Company Fact Sheet
co.don® AG manufactures cell-based biological therapeutics of highest quality in the major orthopedic and neurosurgical markets.
Current indications for company’s products include treatment of articular focal cartilage defects, lumbar disc herniation, non-union fractures and dental disorders.
Further intended indications include treatment of osteoarthritis, as well as rheumatoid arthritis, both markets with unmet needs and blockbuster potential.
The company believes the best, most efficient cells, are grown by using the patient’s own sera and cells without adding antibiotics, exogenous growth factors or any genetically-engineered manufacturing methods.
co.don®’s platform technology is well-suited to achieve this goal:
“we grow the best cells - YOURS!”
All marketing and sales-related activities, from logistics up to user trainings, manufacturing and quality assurance, are focused on achieving superior product performance and manufacturing excellence.
All products are manufactured by using the company’s platform technology, Integrated Isolator Technology (IIT), a worldwide unique production facility certified according to current Good Manufacturing Practices (GMP). This technology was awarded the “First Prize for Pharmaceutical Technology” at the annual meeting of the German Pharmaceutical Industry Association (BPI).
With Integrated Isolator Technology co.don® AG set a new standard in cell manufacturing, ensuring the highest quality level.
With its current products, worldwide best manufacturing facilities, patented technologies and a promising pipeline co.don® AG is clearly positioned for growth.
